Authors:
DWAMENA BA
SHREVE PD
QUINT LE
SHAPIRO B
GROSS MD
WAHL RL
Citation: Ba. Dwamena et al., DISTINGUISHING ADRENAL METASTASES FROM ADENOMAS - A PROSPECTIVE FDG-PET STUDY, Journal of investigative medicine, 46(7), 1998, pp. 284-284
Authors:
FIG LM
BROWN RS
VONMOLL L
APPELMAN HD
STEVENS R
HARNESS J
AUGUST D
SONDAK VK
CHANG AE
ZASADNY KR
FISHER SJ
JOHNSON JW
WICHA MS
COLCHER D
LICHTER AS
WAHL RL
Citation: Lm. Fig et al., IMMUNOLYMPHOSCINTIGRAPHY IN BREAST-CANCER - EVALUATION USING I-131-LABELED MONOCLONAL-ANTIBODY B72.3, Nuclear medicine and biology, 25(3), 1998, pp. 251-260
Citation: Dj. Macfarlane et al., PROSPECTIVE EVALUATION OF 2-[F-18]-2-DEOXY-D-GLUCOSE POSITRON-EMISSION-TOMOGRAPHY IN STAGING OF REGIONAL LYMPH-NODES IN PATIENTS WITH CUTANEOUS MALIGNANT-MELANOMA, Journal of clinical oncology, 16(5), 1998, pp. 1770-1776
Citation: Y. Sugawara et al., PRECLINICAL AND CLINICAL-STUDIES OF BONE-MARROW UPTAKE OF FLUORINE-18-FLUORODEOXYGLUCOSE WITH OR WITHOUT GRANULOCYTE-COLONY-STIMULATING FACTOR DURING CHEMOTHERAPY, Journal of clinical oncology, 16(1), 1998, pp. 173-180
Authors:
SUGAWARA Y
BRAUN DK
KISON PV
RUSSO JE
ZASADNY KR
WAHL RL
Citation: Y. Sugawara et al., RAPID DETECTION OF HUMAN INFECTIONS WITH F-18 FLUORODEOXYGLUCOSE AND POSITRON-EMISSION-TOMOGRAPHY - PRELIMINARY-RESULTS, European journal of nuclear medicine, 25(9), 1998, pp. 1238-1243
Citation: Rl. Wahl, I-131 ANTI-B1 ANTIBODY THERAPY IN NON-HODGKINS-LYMPHOMA - DOSIMETRY AND CLINICAL IMPLICATIONS, The Journal of nuclear medicine, 39(8), 1998, pp. 1-1
Citation: Rl. Wahl et al., PATIENT-SPECIFIC WHOLE-BODY DOSIMETRY - PRINCIPLES AND A SIMPLIFIED METHOD FOR CLINICAL IMPLEMENTATION, The Journal of nuclear medicine, 39(8), 1998, pp. 14-20
Authors:
WAHL RL
ZASADNY KR
MACFARLANE D
FRANCIS IR
ROSS CW
ESTES J
FISHER S
REGAN D
KROLL S
KAMINSKI MS
Citation: Rl. Wahl et al., I-131 ANTI-B1 ANTIBODY FOR B-CELL LYMPHOMA - AN UPDATE ON THE MICHIGAN PHASE-I EXPERIENCE, The Journal of nuclear medicine, 39(8), 1998, pp. 21-27
Authors:
GATES VL
CAREY JE
SIEGEL JA
KAMINSKI MS
WAHL RL
Citation: Vl. Gates et al., NONMYELOABLATIVE I-131 ANTI-B1 RADIOIMMUNOTHERAPY AS OUTPATIENT THERAPY, The Journal of nuclear medicine, 39(7), 1998, pp. 1230-1236
Authors:
SCHELBERT HR
HOH CK
ROYAL HD
BROWN M
DAHLBOM MN
DEHDASHTI F
WAHL RL
Citation: Hr. Schelbert et al., PROCEDURE GUIDELINE FOR TUMOR IMAGING USING FLUORINE-18-FDG, The Journal of nuclear medicine, 39(7), 1998, pp. 1302-1305
Authors:
LEDERMAN RJ
RAYLMAN RR
FISHER SJ
KISON PV
SAN H
NABEL EG
WAHL RL
Citation: Rj. Lederman et al., DETECTION OF ATHEROSCLEROSIS USING A NOVEL POSITRON-SENSITIVE PROBE AND F-18 DEOXYGLUCOSE, The Journal of nuclear medicine, 39(5), 1998, pp. 4-4
Citation: T. Torizuka et al., EFFECT OF DIABETES ON FDG UPTAKE IN UNTREATED PRIMARY LUNG-CANCER, The Journal of nuclear medicine, 39(5), 1998, pp. 162-162
Citation: Rl. Wahl et al., QUALITATIVE CRITERIA FOR DETERMINING IF A SOLITARY PULMONARY NODULE IS MALIGNANT OR BENIGN ON FDG PET - IMPACT OF NOT ACCOUNTING CORRECTLY FOR SOFT-TISSUE ATTENUATION, The Journal of nuclear medicine, 39(5), 1998, pp. 164-164
Authors:
SHREVE P
KALF V
KISON PV
STEVENTON RS
WAHL RL
Citation: P. Shreve et al., LESION DETECTION THRESHOLDS OF POSITRON IMAGING CAMERAS - PHANTOM STUDIES CORRESPONDING TO CLINICAL CONDITIONS, The Journal of nuclear medicine, 39(5), 1998, pp. 194-194
Authors:
SHREVE P
STEVENTON RS
DETERS E
GROSS MD
WAHL RL
Citation: P. Shreve et al., LESION DETECTION IN ONCOLOGIC DIAGNOSIS - COMPARISON OF DUAL HEAD COINCIDENCE WITH DEDICATED PET FDG IMAGING, The Journal of nuclear medicine, 39(5), 1998, pp. 426-426
Authors:
KORAL KF
DEWARAJA Y
LI J
LIN S
REGAN D
ZASADNY KR
FRANCIS I
KAMINSKI MS
WAHL RL
Citation: Kf. Koral et al., PRELIMINARY-REPORT OF TUMOR DOSIMETRY FROM I-131 SPECT OF PREVIOUSLY-UNTREATED PATIENTS WITH B-CELL LYMPHOMA, The Journal of nuclear medicine, 39(5), 1998, pp. 437-437
Authors:
TORIZUKA T
ZASADNY KR
KISON PV
ROMMELFANGER SG
KAMINSKI MS
WAHL RL
Citation: T. Torizuka et al., RESPONSE OF NON-HODGKINS-LYMPHOMA TO NONMYELOABLATIVE 1-13-I-ANTI-B1 RADIOIMMUNOTHERAPY - EVALUATION WITH FDG PET, The Journal of nuclear medicine, 39(5), 1998, pp. 579-579
Citation: Sg. Rommelfanger et al., DOSIMETRY OF I-131 ANTI-B1 (ANTI-CD20) ANTIBODY FOR NON-HODGKINS-LYMPHOMA - COMPARISON OF UP-FRONT TREATMENT VS. CHEMOTHERAPY-REFRACTORY PATIENTS, The Journal of nuclear medicine, 39(5), 1998, pp. 840-840
Citation: Kr. Zasadny et al., PRACTICAL TUMOR-ACTIVITY QUANTIFICATION STRATEGIES IN 2D AND 3D PET, The Journal of nuclear medicine, 39(5), 1998, pp. 1136-1136
Authors:
JAMADAR DA
KAZEROONI EA
MARTINEZ FJ
KRITZMAN J
WAHL RL
Citation: Da. Jamadar et al., PREDICTION OF CLINICAL OUTCOME AFTER LVRS - COMPARISON OF QUANTITATIVE COMPUTER-GENERATED RATIO OF UPPER LOWER LUNG PERFUSION WITH SEMIQUALITATIVE SCORING OF PERFUSION DEFECTS IN THE UPPER AND LOWER LUNGS ON 99M-MAA TECHNETIUM/, Radiology, 209P, 1998, pp. 298-298
Citation: Ba. Dwamena et al., SHOULD FDG-PET REPLACE CT OR BE USED COMPLEMENTARY TO CT IN THE MEDIASTINAL STAGING OF NSCLC - CLINICAL AND ECONOMIC-CONSIDERATIONS, Radiology, 209P, 1998, pp. 657-657